Investment analysts at Aegis assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report issued on Tuesday. The firm set a “buy” rating and a $21.00 price target on the biopharmaceutical company’s stock. Aegis’ target price indicates a potential upside of 55.79% from the stock’s previous close.
A number of other equities analysts also recently commented on the company. Zacks Investment Research upgraded Nektar Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price target for the company in a research note on Tuesday, July 19th. Jefferies Group reiterated a “buy” rating on shares of Nektar Therapeutics in a research note on Thursday, September 8th. Brean Capital reiterated a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a research note on Friday, September 30th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $21.00 price target (up from $17.00) on shares of Nektar Therapeutics in a research note on Friday, August 5th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $20.50.
Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up 1.58% during trading on Tuesday, hitting $13.48. The stock had a trading volume of 386,957 shares. The firm’s 50-day moving average is $13.84 and its 200-day moving average is $15.68. Nektar Therapeutics has a one year low of $10.52 and a one year high of $19.98. The firm’s market cap is $2.06 billion.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.04. The business earned $36.30 million during the quarter, compared to the consensus estimate of $32.42 million. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The company’s revenue for the quarter was down 39.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.06) earnings per share. Equities research analysts forecast that Nektar Therapeutics will post ($1.07) EPS for the current year.
In other Nektar Therapeutics news, Director R Scott Greer acquired 15,000 shares of Nektar Therapeutics stock in a transaction dated Monday, October 24th. The stock was acquired at an average cost of $13.50 per share, for a total transaction of $202,500.00. Following the completion of the transaction, the director now owns 121,333 shares in the company, valued at approximately $1,637,995.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert Chess sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $19.21, for a total value of $230,520.00. The disclosure for this sale can be found here. 6.10% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of the company. Bridger Management LLC purchased a new stake in shares of Nektar Therapeutics during the first quarter valued at approximately $48,359,000. Cormorant Asset Management LLC boosted its stake in shares of Nektar Therapeutics by 161.4% in the first quarter. Cormorant Asset Management LLC now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $27,500,000 after buying an additional 1,234,844 shares during the last quarter. Westfield Capital Management Co. LP purchased a new stake in shares of Nektar Therapeutics during the second quarter valued at approximately $17,247,000. BlackRock Fund Advisors boosted its stake in shares of Nektar Therapeutics by 7.3% in the third quarter. BlackRock Fund Advisors now owns 10,970,974 shares of the biopharmaceutical company’s stock valued at $188,481,000 after buying an additional 749,496 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Nektar Therapeutics by 97.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,156,400 shares of the biopharmaceutical company’s stock valued at $19,867,000 after buying an additional 571,900 shares during the last quarter. Institutional investors and hedge funds own 86.69% of the company’s stock.
Nektar Therapeutics Company Profile